Instil Bio(TIL) - 2024 Q2 - Quarterly Results

Instil Bio Reports Second Quarter 2024 Financial Results and Provides Corporate Update – In-licensed SYN-2510/IMM2510, a potentially best-in-class PD-L1xVEGF bispecific antibody, and SYN27M/IMM27M, a next-generation ADCC-enhanced anti-CTLA-4 antibody – Entered into a 15-year lease for our cell therapy manufacturing facility to AstraZeneca Pharmaceuticals LP DALLAS, TX, August 13, 2024 (GLOBE NEWSWIRE) Instil Bio, Inc. ("Instil") (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing ...